CAMPAT IN THE THERAPY OF CHRONIC LYMPHOCITIC LEUKEMIA: ACHIEVEMENTS AND PERSPECTIVES
Thisreviewsummarizesdataontheexperiences of a new class of drugs for the treatment of chronic lymphocytic leukemia — mAbs to the SD52, the drug Alemtuzumab (Campath). A review of randomized clinical studies on efficacy and safety of Campath, an analysis of the possible application of the drug in different clinical situations — in refractory and relapse of the disease, as consolidation of remission and as first-line treatment. The world experience of the intravenous and subcutaneous routes of drug’s administration.
No comments » Add comment